Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pancreatic dysfunction and treatment options

T Nakamura1, T Takeuchi, Y Tando

  • 1Third Department of Internal Medicine, Hirosaki University School of Medicine, Aomori, Japan.

Pancreas
|April 21, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatocyte growth factor is linked by O-glycosylated oligosaccharide on the alpha chain.

Biochemical and biophysical research communications·1992
Same author

Proteolytic activation of a single-chain precursor of hepatocyte growth factor by extracellular serine-protease.

Biochemical and biophysical research communications·1992
Same author

Growth stimulation of rat fetal hepatocytes in response to hepatocyte growth factor: modulation of c-myc and c-fos expression.

Biochemical and biophysical research communications·1992
Same author

Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids.

The Journal of biological chemistry·1992
Same author

ECM gene expression and its modulation by insulin in diabetic rats.

Diabetes·1992
Same author

Rapid and marked induction of hepatocyte growth factor during liver regeneration after ischemic or crush injury.

Hepatology (Baltimore, Md.)·1992
Same journal

ITGB4 Activates the Pentose Phosphate Pathway to Reduce the Sensitivity of Pancreatic Adenocarcinoma to Gemcitabine.

Pancreas·2026
Same journal

AI-driven Test-Free Prediction of ICU Admission, Insulin Dependence, and Exocrine Dysfunction after Acute Pancreatitis.

Pancreas·2026
Same journal

Redefining Prognosis in Acute Pancreatitis: The Emerging Role of Antioxidant Biomarkers.

Pancreas·2026
Same journal

Commentary on "High Rate of Exocrine Pancreatic Dysfunction in Pediatric Patients with Diabetes Mellitus".

Pancreas·2026
Same journal

Pancreatic Ductal Adenocarcinoma (PDAC) Arising from Mixed Duct Intraductal Papillary Mucinous Neoplasm (IPMN) can Mimic Multifocal Pseudocyst.

Pancreas·2026
Same journal

Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Pancreas·2026
See all related articles

Pancreatic enzyme replacement therapy is key for chronic pancreatitis (CP) patients with steatorrhea and diabetes. Careful enzyme selection and monitoring are crucial for managing nutritional status and improving outcomes.

Area of Science:

  • Gastroenterology
  • Endocrinology
  • Nutritional Science

Background:

  • Chronic pancreatitis (CP) decompensation presents with pancreatic steatorrhea and diabetes, leading to severe nutritional disturbances, hypoglycemia, and infections.
  • Pancreatic enzyme replacement therapy (PERT) is the primary treatment for pancreatic steatorrhea in CP.
  • Evaluating dietary fat intake and pancreatic exocrine function is essential before initiating PERT.

Purpose of the Study:

  • To review the principles and considerations for pancreatic enzyme replacement therapy in chronic pancreatitis.
  • To discuss various enzyme preparations and adjunct therapies.
  • To highlight the importance of monitoring treatment efficacy and nutritional status.

Main Methods:

  • Review of current literature on pancreatic enzyme replacement therapy for chronic pancreatitis.

Related Experiment Videos

  • Discussion of different enzyme formulations (porcine pancreatin, bacterial lipase, fungal lipase) and delivery systems (conventional, entero-coating, microspheres).
  • Consideration of factors influencing therapy, including gastric acid suppression and patient monitoring.

    • Main Results:

    • PERT is effective for pancreatic steatorrhea, but requires careful selection of enzyme type and dosage.
    • Various preparations exist, each with strengths and weaknesses regarding acid protection and release profile.
    • Concomitant use of gastric acid suppressants may be beneficial.
    • Regular monitoring of fecal fats, body weight, and nutritional indices is vital.

    Conclusions:

    • Effective management of pancreatic steatorrhea in CP involves individualized PERT, considering enzyme properties and patient factors.
    • Close monitoring of treatment response and nutritional status is critical for optimizing patient care.
    • Further research is needed on the interplay between carbohydrate maldigestion and pancreatic diabetes treatment in CP.